DynaPro Plate Reader Optimizes Screening Process for Biotherapeutic Candidates and Formulations
Wyatt Technology Corporation highlights a study recently authored by Martin Skov Neergaard from the Faculty of Health and Medical Sciences at the University of Copenhagen, “Protein-Protein Interactions Investigated by DLS: Determination at High and Low Protein Concentration.” This article outlines the benefits of quantifying protein-protein interactions (PPI) using automated dynamic light scattering (DLS) in high-throughput screening (HTS) mode to identify promising candidates for drug-like properties and establish the suitability of formulations before entering extended stability studies. The study, which used Wyatt Technology’s DynaPro Plate Reader II high-throughput DLS instrument, was published by GIT Laboratory and may be downloaded at www.wyatt.com/AppNotes/DLS.
Therapeutic monoclonal antibodies (mAbs) are effective at treating chronic diseases such as autoimmune disorders and cancer. Long-term stability is an important attribute of any commercial drug molecule, and of great interest in biotherapeutics in particular. Measurements of PPI indicate colloidal stability, correlate closely to stability and viscosity at high protein concentration, and are widely used as stability-indicating parameters (SIPs) in pre-selecting monoclonal antibody biotherapeutic molecules and formulation conditions before launching the arduous process of long-term stability testing. Ordinarily, PPI studies require significant quantities of sample and labor. Optimal screening processes of PPI will allow drug developers to identify and concentrate development on the most promising mAbs and formulations, saving considerable time and money while decreasing time-to-market.
The study showcases some novel uses of DLS to rapidly provide substantial information about the stability and viscosity of a formulation. Traditionally, PPI are quantified by static light scattering (SLS) as the second virial co-efficient (B22), though recently other techniques have come into widespread use. DLS has proven extremely useful in this field as it provides substantially more information regarding SIPs, with less sample, than standard SLS. DLS quantifies PPI via the diffusion interaction parameter (kD), and Neergaard also explored the relative radius method comparing apparent hydrodynamic radii at low and high concentrations. These methods, using kD and relative radius to quantify PPI in a protein solution, make the process of characterization much quicker and simpler than standard methods.
The DynaPro Plate Reader II is capable of running high-throughput, automated HTS-DLS analyses to characterize PPI in standard microwell plates, under multiple conditions in a significantly reduced time frame, making DLS a viable option for SIP screening. As an added benefit, DLS measures the viscosity of highly concentrated proteins with the same high throughput and low sample consumption. The onset points of aggregation or melting may be obtained in the DynaPro via temperature ramps or chemical denaturing, to assess additional SIPs for conformational stability, making the DynaPro DLS plate reader the ultimate tool for developability and formulation screening.
“Techniques for determining protein stability are still widely debated amongst researchers, and a combination of stability-indicating parameters must be weighed to get a complete picture,” explains Dr Daniel Some, Director of Marketing and Principal Scientist at Wyatt Technology, “Optimization of screening processes to reduce time and resources spent on ensuring long-term viability is a key consideration in the drug development process. The DynaPro Plate Reader II ensures comprehensive testing, over a range of conditions in minimal time, and eliminates the need for additional laboratory apparatus when screening the stability-indicating parameters of high concentration protein formulations.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...